RVMD ESMO subgroup OS data consistent with prior efficacy, but valuation remains stretched

What happened

Revolution Medicines presented exploratory subgroup analyses from Phase 3 RASolute 302 at ESMO 2026, showing daraxonrasib provided consistent overall survival benefit over chemotherapy across all evaluated RAS genotype subgroups in previously treated metastatic pancreatic cancer, including patients with no identified tumor RAS mutation. This is supportive clinical news but is not a final readout and does not change the trial's primary endpoint timeline or the binary risk ahead. The DeepValue master report already priced in strong efficacy potential for daraxonrasib, with a base scenario implied value of $90 versus the current share price of $98, and a bear case of $60 if real-world efficacy disappoints. The stock's premium market capitalization of ~$19 billion and negative earnings reflect high odds of approval and M&A optionality, but this subgroup data is unlikely to trigger further re-rating as it aligns with existing expectations. Our prior judgment of 'POTENTIAL SELL' with conviction 4.0 remains valid, as near-term fundamentals still lack catalysts to justify additional upside from here.

Implication

The ESMO data reinforces daraxonrasib's broad activity, which slightly de-risks the bear case but does not materially change the base or bull scenarios. With shares at $98, above the base implied value of $90 and well above the bear case $60, the risk/reward is skewed to the downside over the next 6-12 months. The next major catalyst remains the Phase 3 RASolute 302 final readout in 2026, and until then, news flow will be incremental and unlikely to drive significant upside. Crowded positioning and recent M&A speculation (AbbVie denial) add sentiment risk if the narrative cools. We maintain our 'POTENTIAL SELL' stance and suggest trimming above $115 or waiting for a pullback toward $75 for a more attractive entry.

Thesis delta

The thesis is unchanged. This ESMO subgroup data confirms consistent overall survival benefit for daraxonrasib but is exploratory and does not alter the probability-weighted outcomes already embedded in our model. Our base case remains $90 with bear $60, and the current price of $98 leaves little room for error.